|
One of the largest and best-designed federal studies of hormone
replacement therapy was halted because women taking the hormones
after menopause had a greater risk of:
- Breast cancer,
- Heart attack,
- Stroke and
- Blood clots
than those who did not take the drugs. The trial, which was to
last for 8.5 years or until 2003, was halted because of a significant
increase in the risk of invasive breast cancer.
More than 6 million women in the US currently take estrogen and
progestin (Prempro) combination therapy for a variety of reasons,
including relief of hot flashes and other menopausal symptoms.
This has significant implications, however on Premarin
was introduced in 1942. It was the
most-prescribed drug in America each year from 1992 through
1999 and perhaps the most prescribed drug ever.
Last year Premarin generated more than $2
billion in sales for Wyeth.
Please recognize that the progestin drug used in this study is
not the same as human progesterone, but a synthetic derivative of
the natural female hormone progesterone. Progestin can actually
kill a fetus if taken when the woman is pregnant. The only reason
it is used the drug companies have a patent on it and can make more
money than the safer natural progesterone.
The confusion about estrogen is that it actually raises levels
of HDL (or "good") cholesterol in women, which is often
considered one of the reasons that a woman's risk of heart disease
is low prior to menopause. For years, HRT was widely believed to
reduce the risk of heart disease in postmenopausal women, but recent
studies have failed to document any protective effects.
The hope -- and the hype of the drug companies -- has been that
estrogen would also confer a reduced risk of heart disease. The
study suggests the exact opposite though, in that when women take
the drugs for more than about 5 years, the
risks of the hormones clearly outweigh the benefits.
The trial involved over 16,000 women aged 50 to 79 who still had
their uterus. Such women are given a combination of estrogen and
progestin, because estrogen alone can promote cancer in the lining
of the uterus. The new findings do not apply to the health effects
of estrogen alone, which is being looked at in a separate study
by researchers at the NHLBI.
The findings support the recent American Heart Association recommendations
that postmenopausal women should not take hormone therapy to lower
their risk for heart disease.
Interestingly this study comes right on the heels of another full
text article that was published the week earlier in JAMA,
which showed the similar negative findings regarding estrogen and
heart disease
The original Heart and Estrogen/Progestin Replacement Study (HERS)
study found that women taking hormone therapy
were up to three times more likely to develop blood clots than those
taking a placebo.
Hormone therapy was also associated with a higher risk of gallbladder
disease surgery in the study. Together, the findings argue that
hormone replacement therapy should not be recommended for postmenopausal
women with heart disease.
JAMA
July 17, 2002;288:321-333 (Free Full Text Article)
|